Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$5.35 - $10.11 $151,720 - $286,709
-28,359 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$7.93 - $13.33 $6,185 - $10,397
780 Added 2.83%
28,359 $265,000
Q4 2021

Feb 11, 2022

BUY
$11.96 - $19.35 $70,575 - $114,184
5,901 Added 27.22%
27,579 $364,000
Q3 2021

Nov 12, 2021

BUY
$17.35 - $24.87 $93,169 - $133,551
5,370 Added 32.93%
21,678 $390,000
Q2 2021

Aug 11, 2021

BUY
$14.25 - $30.93 $12,810 - $27,806
899 Added 5.83%
16,308 $391,000
Q1 2020

May 06, 2020

BUY
$5.79 - $11.78 $5 - $11
1 Added 0.01%
15,409 $100,000
Q4 2019

Feb 14, 2020

SELL
$9.47 - $16.71 $568 - $1,002
-60 Reduced 0.39%
15,408 $163,000
Q3 2019

Nov 07, 2019

SELL
$15.74 - $23.65 $13,441 - $20,197
-854 Reduced 5.23%
15,468 $262,000
Q2 2019

Aug 12, 2019

BUY
$19.88 - $25.0 $12,106 - $15,225
609 Added 3.88%
16,322 $408,000
Q1 2019

May 14, 2019

BUY
$18.38 - $24.44 $4,227 - $5,621
230 Added 1.49%
15,713 $344,000
Q3 2018

Nov 09, 2018

BUY
$20.96 - $30.77 $78,830 - $115,725
3,761 Added 32.08%
15,483 $0
Q2 2018

Aug 06, 2018

BUY
$16.13 - $26.99 $189,075 - $316,376
11,722 New
11,722 $291,000

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $187M
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.